Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The disease burden of typhoid fever remains high in endemic areas in Asia and Africa, especially in children. Recent clinical trials conducted by the Typhoid Vaccine Acceleration Consortium show typhoid conjugate vaccine (TCV) to be safe, immunogenic, and efficacious at preventing blood culture-confirmed typhoid fever in African and Asian children. Pakistan, Liberia, and Zimbabwe recently introduced TCV through campaigns and routine childhood immunizations, providing protection for this vulnerable population. It is essential to continue this momentum while simultaneously filling data gaps-including typhoid complications-to inform decision-making on TCV introduction. A multidisciplinary approach including surveillance, water, sanitation, and hygiene investments, and large-scale TCV introduction is needed to decrease the burden and mortality of typhoid fever.

Original publication

DOI

10.1093/infdis/jiab449

Type

Journal article

Journal

The Journal of infectious diseases

Publication Date

12/2021

Volume

224

Pages

S781 - S787

Addresses

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Keywords

Humans, Salmonella typhi, Typhoid Fever, Typhoid-Paratyphoid Vaccines, Vaccines, Conjugate, Public Health, Child, Immunization Programs, Zimbabwe, Pakistan, Immunogenicity, Vaccine, Vaccine Efficacy